Tadekinig alfa - Merck Serono

Drug Profile

Tadekinig alfa - Merck Serono

Alternative Names: IL-18 binding protein - Merck Serono; IL-18bp - Merck Serono; Interleukin-18 binding protein - Merck Serono; r-IL-18 bp - Merck Serono; Tadekinig-α - Merck Serono

Latest Information Update: 08 Apr 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yeda Research and Development Company Ltd
  • Class Anti-inflammatories; Recombinant proteins
  • Mechanism of Action Interleukin 18 inhibitors; Th1 cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders

Most Recent Events

  • 08 Jan 2007 Serono is now called Merck Serono
  • 05 Jan 2007 Serono has been acquired by Merck KGaA
  • 27 Jan 2005 Discontinued - Phase-I for Crohn's disease in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top